title: [Analysis of risk factor treatment failures in therapeutic programme for malignant germ cell tumours in children. Multicentre prospective study of Polish Pediatric Group for Solid Tumours 1998--2006].
abstract: OBJECTIVE
  The aim of the study was the analysis of risk factors of therapeutic failures in children with malignant germ cell tumours treated within the multicentre programme of PPGGL from 1999--2006.
  
  
  METHODS
  The investigated group included 18 (14.3%) patients, of 123 who have finished the treatment of malignant germ cell tumour, in whom no remission was obtained or relapse occurred. All the patients were treated according to the TGM 95 programme. Both clinical and morphological data of the group have been analysed.
  
  
  RESULTS
  Among 18 patients with therapeutic failures 12 died. Two patients from the high risk group died of complications of the treatment--sepsis during neutropenia after chemotherapy and one after haemorrhage to the central nervous system. The other 9 died from progression of malignancy, 6 of them belonged to the high risk group. 10 (82%) of 12 patients who died had extragonadal location and in 11 (92%) the tumour was in stage III or IV of the disease. The most frequent histology in this group was mixed germ cell tumour with component of yolk sac tumour or carcinoma embrionale. 92% patients had elevated AFP, in 4 it was above 15000 ng/ml. In 11 (92%) patients primary chemoresistance was observed, and radical surgery was not possible for the reason of advanced stage of the disease. In 6 patients relapse occurred. In 3 patients testis was the primary location (I and II stage), in 3 patients the tumour was localized in the sacrococcygeal region (III and IV stage). All the patients are alive in remission after second line therapy, with 78 months (median) of follow-up.
  
  
  CONCLUSIONS
  1. The main risk factor for therapeutic failures in malignant germ cell tumours was primary chemoresistance in inoperable tumours of the sacrococcygeal region. 2. The mortality of treatment complications was low. 3. The relapse of cancer was not a risk factor for therapeutic failure due to the high probability of second remission 4. Therapeutic failures are mainly observed in patients with mixed germ cell tumour with components of yolk sac tumour or carcinoma embrionale. 5. Tumour chemoresistance should be considered an essential factor in identifying high risk patients.
authors.affiliation: Klinika Pediatrii, Gastroenterologii i Onkologii Dzieciecej, Akademia Medyczna, ul. Nowe Ogrody 1-6, 80-803 Gdańsk, Poland.
authors.forename: Stefan
authors.initials: S
authors.lastname: Popadiuk
authors.forename: Maria
authors.initials: M
authors.lastname: Korzon
authors.forename: Alicja
authors.initials: A
authors.lastname: Chybicka
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Szmyd
authors.forename: Walentyna
authors.initials: W
authors.lastname: Balwierz
authors.forename: Joanna
authors.initials: J
authors.lastname: Trelinska
authors.forename: Jerzy
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: Hanna
authors.initials: H
authors.lastname: Wisniewska-Slusarz
authors.forename: Wojciech
authors.initials: W
authors.lastname: Woźniak
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Bilska
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiak
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Maryna
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Szumera
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Sznurkowska
authors.forename: Joanna
authors.initials: J
authors.lastname: Renke
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000628:therapy*; D011044:Poland; D012307:Risk Factors; D017211:Treatment Failure